<DOC>
	<DOCNO>NCT02433353</DOCNO>
	<brief_summary>Approximately 150 active duty service member meet Diagnostic Statistical Manual version 5 ( DSM-5 ) criterion posttraumatic stress disorder ( PTSD ) score 50 Clinician Administered PTSD Score DSM-5 ( CAPS-5 ) recruit . Qualifying participant randomize 1:1 basis either eye movement desensitization reprocessing ( EMDR ) plus venlafaxine XR group EMDR plus placebo group . Protocol call participant complete 12 one-hour EMDR session take venlafaxine XR/placebo dose 150mg 225mg entire 24 week . Both prescribers therapist blind CAPS-5 assessment complete individual involve participant 's direct treatment . An unblinded pharmacist dispense medication placebo accord instruction prescriber count remain tablet measure compliance . All EMDR session record review principal investigator use fidelity checklist . CAPS-5 administered completion EMDR 6 month date his/her first therapy session .</brief_summary>
	<brief_title>Results From 24 Week Trial EMDR Combined With Venlafaxine XR</brief_title>
	<detailed_description>Approximately 150 active duty service member meet DSM-5 criterion PTSD score 50 Clinician Administered PTSD Score DSM-5 ( CAPS-5 ) recruit prospective , randomize , double-blinded , controlled trial . Participants recruit via referral provider self-referral recruitment flier . CAPS-5 consider gold-standard PTSD symptom assessment research . An initial PHQ-9 , PCL-5 , urine drug screen , pregnancy test obtain visit well . Qualifying participant meet prescriber , review informed consent , draw number randomization , complete SCID-5 . The participant meet pharmacist dispense either venlafaxine XR placebo . Randomization occur participant recruit . Randomization consist use random number generator generate 150 number . The pharmacist secretly assign half number treatment half control . Numbers generate write slips paper place opaque envelope place box . Participants draw number inform researcher number drawn . The titration schedule venlafaxine XR/placebo 3 day 37.5mg , 7 day 75mg , increase 150mg . The participant meet prescriber 4 week 150mg determine increase 225mg warrant base participant DSM-5 PTSD symptom . Meetings prescriber occur monthly throughout study unless side effect concern require frequent follow . Prescriber visit schedule 30 minute , however , visit could complete little five minute medication work well side effect , blood pressure remain baseline , participant remain adherent medication therapy , participant raise concern . Participants meet pharmacist monthly basis pill count . EMDR session occur weekly possible less every 2 week . Two session allow 1 week participant anticipate go field otherwise unavailable regular visit . All EMDR session record use camcorder principal investigator review 10 % therapy session ( minimum 1 session per participant ) use fidelity checklist . CAPS-5 assessment complete individual involve participant 's direct treatment administer completion EMDR 6 month date his/her first therapy session . A urine drug screen order CAPS-5 . Missing data/participant drop handle use last object carry forward . Comparisons intervention compute use student 's T-test single comparison group ANOVA multiple comparisons/time point involve . If point participant request record treatment , summary care provide .</detailed_description>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Inclusion : Initial CAPS5 score 50 great Meeting criterion PTSD use DSM5 criterion Open active duty US service member gender , race / ethnicity , religion , sexual orientation , marital status Participants history mild TBI , past current substance abuse , nicotine dependence , chronic pain , migraines/headaches , medical illness specify exclusion section Participants take opiate , sleep aid , and/or prazosin indication PTSD nightmares provide dose exceed 15mg ( men ) / 9mg ( woman ) . Dosing per day permit Exclusion : Current suicidal homicidal ideation Pregnancy Profound hearing loss HIV AIDS Current chemotherapy Primary think disorder Bipolar disorder cyclothymia Current substance dependence ( include nicotine ) Current use bupropion 150mg daily Current use mirtazapine 15mg daily Current use SSRI Current use another SNRI Current use tricyclic antidepressant dose 50mg Current use MAOI Current use stimulant Current use mood stabilizer/antiepileptic indication mood stability reduction anger Current use antipsychotic Current use lithium Chronic daily use steroid Current use tapentadol Current use dronabinol Current use ketamine</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>PTSD</keyword>
	<keyword>posttraumatic stress disorder</keyword>
	<keyword>venlafaxine</keyword>
	<keyword>EMDR</keyword>
	<keyword>eye movement desensitization reprocess</keyword>
	<keyword>antidepressant</keyword>
	<keyword>psychotherapy</keyword>
</DOC>